William Blair analyst Matt Larew has maintained their bullish stance on OPCH stock, giving a Buy rating on October 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Buy rating due to a combination of factors that highlight Option Care Health’s strong financial performance and strategic positioning. The company has consistently exceeded expectations, marking its 23rd consecutive quarter of delivering results that surpass revenue, adjusted EBITDA, and adjusted EPS estimates. This consistent outperformance has led management to raise its full-year guidance, reflecting confidence in continued growth despite challenges such as the Stelara headwind.
Additionally, Option Care Health’s strategic initiatives, including market share gains and acquisitions like INTRAMED Plus, have contributed to its robust revenue growth. The company’s shares are trading at a discount compared to peers and its historical averages, presenting a potential value opportunity for investors. These factors, combined with a solid outlook and strategic capital deployment plans, underpin Larew’s positive assessment and Buy rating for the stock.
According to TipRanks, Larew is a 2-star analyst with an average return of 0.2% and a 47.76% success rate. Larew covers the Healthcare sector, focusing on stocks such as Thermo Fisher, AptarGroup, and Option Care Health.
In another report released on October 18, TR | OpenAI – 4o also upgraded the stock to a Buy with a $31.00 price target.